Urovant Sciences

$15.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
-$0.25 (-1.55%) As of 7:19 PM EST after-hours

Why Robinhood?

You can buy or sell UROV and other stocks, options, and ETFs commission-free!

About UROV

Urovant Sciences Ltd. Common Stock, also called Urovant Sciences, is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. The listed name for UROV is Urovant Sciences Ltd. Common Stock.

CEO
James A. Robinson
Employees
Headquarters
London, Greater London
Founded
2016
Market Cap
511.98M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.34M
High Today
$16.20
Low Today
$16.13
Open Price
$16.20
Volume
384.09K
52 Week High
$16.25
52 Week Low
$6.55

Collections

UROV Earnings

-$1.54
-$1.03
-$0.51
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Expected Feb 11, After Hours

You May Also Like